PROFUSA, Inc. PFSA

Profusa received a positive decision from GMED on ISO 13485 certification for its quality management system and expects formal certification in early October, a step in the Lumee Oxygen Platform’s CE-mark process. The company still must complete Medical Device Regulation conformity assessments before an MDR certificate can be issued, after which CE marking could demonstrate compliance with EU requirements for the 27 member states. Profusa cautioned there is no guarantee on the timing or outcome of the remaining MDR work, or when CE marking may occur. The Lumee Oxygen Platform uses a tissue-integrated biosensor to monitor tissue oxygen in real time, with potential European commercialization tied to CE clearance. Profusa also notes an option to acquire G3 Vision Labs could influence its broader diagnostics strategy. ISO 13485 certification advances the European regulatory path toward CE marking, but remaining MDR assessments and timing uncertainty keep the outcome uncertain.

Profusa, Inc. received a Nasdaq compliance determination. Nasdaq compliance status directly influences listing continuity and short-term investor sentiment.

Profusa reports Q2 2026 financial results and advances option agreement conditions toward close with G3 Vision Labs. Quarterly results plus progress on deal closure with diagnostics firm represent major strategic move likely to shift trajectory and sentiment.

PROFUSA advances conditions for G3 Vision Labs acquisition while reporting wider Q2 net loss. Acquisition progress signals strategic expansion potential despite widened quarterly losses.

Profusa is vying to acquire G3 Vision Labs. Potential acquisition of G3 Vision Labs marks a major strategic move that could reshape Profusa's operations and market position.

Profusa signs option agreement to acquire G3 Vision Labs, a commercial stage diagnostics company. Option to acquire diagnostics company marks major strategic expansion with direct effects on operations and positioning.

Profusa signs term sheet for diagnostics acquisition and announces leadership changes. Term sheet for diagnostics acquisition plus leadership changes mark major strategic moves likely to shift company trajectory and investor views.

Profusa announces key management changes and signs non-binding term sheet to acquire a commercial stage diagnostics company. Management overhaul plus non-binding acquisition term sheet mark major strategic moves that can shift company trajectory and investor sentiment.

PROFUSA shareholders approved strategic initiatives at the 2026 Annual Meeting to support the PanOmics acquisition, strengthen the balance sheet, and achieve Nasdaq compliance. Shareholder approval advances PanOmics acquisition, balance sheet improvements, and Nasdaq compliance, materially shifting company trajectory.

Profusa submits response package to GMED as part of ongoing CE Mark review process for Lumee Oxygen Platform. CE Mark submission advances regulatory path toward European market access for core product.

Profusa Inc. (PFSA) announces transfer of its listing to The Nasdaq Capital Market. Nasdaq listing transfer significantly boosts visibility, liquidity, and investor sentiment for Profusa.

Quantum Cyber's stock has more than doubled today due to two key reasons. Stock price more than doubling represents a game-changing surge in market performance and investor sentiment for PROFUSA (PFSA).

Profusa, Inc. (PFSA) received a favorable Nasdaq listing determination, resolving prior compliance issues and allowing continued listing on the exchange. Favorable Nasdaq determination avoids delisting risk, enhancing stock liquidity, investor confidence, and market performance.

Profusa Inc. (PFSA) board initiates process to evaluate strategic alternatives and maximize shareholder value. Board-led strategic review signals potential sale, merger, or restructuring, significantly impacting future trajectory and investor sentiment.

Profusa Inc. (PFSA) secures $30M letter of intent for PanOmics platform, expanding into multi-billion dollar precision diagnostics market. $30M LOI enables entry into multi-billion dollar precision diagnostics market, marking major strategic expansion with potential to significantly boost revenue and valuation.

Profusa, Inc. (PFSA) to withdraw its S-1 registration statement to pursue a smaller, more focused offering. Withdrawal of S-1 for a smaller offering represents a major strategic pivot in capital-raising plans, potentially delaying growth and altering investor sentiment.

PROFUSA, Inc. (PFSA) received purchase orders for its Lumee™ Tissue Oxygen Monitoring product and raised its 2026 revenue guidance. Purchase orders confirm product market validation while raised revenue guidance signals accelerated growth and positive investor sentiment.

Profusa, Inc. has partnered with Mayo Clinic to enhance clinical applications of its oxygen monitoring technologies. This collaboration aims to leverage advanced monitoring solutions to improve patient care and outcomes, focusing on high-impact clinical scenarios. The partnership is expected to drive innovation and expand the use of Profusa's technology in healthcare settings. The collaboration with Mayo Clinic is likely to significantly enhance product development and market positioning for Profusa's oxygen monitoring technologies.

Profusa, Inc. has partnered with Mayo Clinic to enhance clinical applications of its oxygen monitoring technologies. This collaboration aims to leverage Mayo Clinic's expertise in clinical research and patient care to advance the development and implementation of these innovative monitoring solutions, potentially improving patient outcomes in various medical settings. The collaboration with Mayo Clinic is expected to significantly enhance product development and market positioning for Profusa's oxygen monitoring technologies.

Profusa, Inc. (PFSA) has announced a 1-for-75 reverse stock split, aimed at increasing the per-share price of its common stock. This move is intended to meet the minimum bid price requirement for continued listing on the Nasdaq stock exchange. The reverse split will take effect on a specified date, and shareholders will receive one new share for every 75 shares they currently own. The company believes this action will enhance its marketability and attract institutional investors. The reverse stock split may improve the stock's market perception and compliance with exchange requirements, but its overall impact on long-term performance remains limited.

Profusa, Inc. presented positive clinical results from a US study at the Leipzig Interventional Course (LINC) 2026, showcasing advancements in their technology and potential applications in healthcare. The findings highlight the effectiveness and reliability of their products, which could enhance patient monitoring and treatment outcomes. Positive clinical results could significantly impact product adoption and investor sentiment.

Profusa, Inc. has launched its Lumee™ Tissue Oxygen healthcare research offerings, marking the initiation of its first commercial revenue. This new product aims to enhance tissue oxygen monitoring, potentially benefiting various healthcare applications and advancing the company's market position. The launch of Lumee™ is a significant strategic move that could alter the company's trajectory and investor sentiment.

Profusa, Inc. has expanded its customer base by adding a prominent vascular surgeon from Greece, enhancing its presence in the medical community and potentially increasing the adoption of its innovative health monitoring technologies. The addition of a leading surgeon to the customer base may moderately influence market sentiment and product adoption.

Profusa, Inc. has expanded its European commercial network by partnering with MedSell as a new distributor in France. This collaboration aims to enhance the distribution of Profusa's innovative tissue-integrated biosensors, which are designed for continuous monitoring of health conditions. The partnership is expected to strengthen Profusa's presence in the European market and improve access to its products for healthcare providers and patients in France. The partnership with MedSell is a significant strategic move that could enhance market penetration and investor sentiment in Europe.

Profusa, Inc. has restructured its senior secured convertible notes, with the new terms allowing conversion only if the stock price exceeds $0.35. This move aims to strengthen the company's financial position and manage its debt more effectively. Restructuring the convertible notes may moderately influence the company's financial stability and investor sentiment.

Profusa, Inc. announced that its U.S. study met primary endpoints, as presented at the Late Breaking Clinical Trials session during the Paris Vascular Insights 2025 conference. The successful results are expected to enhance the company's position in the market and support its ongoing development efforts. Meeting primary endpoints in a clinical study is a significant milestone that can positively influence future performance and investor sentiment.

Profusa, Inc. will present clinical data from its US study at the Leipzig Interventional Course (LINC) 2026. This presentation is expected to showcase advancements in the company's technology and its implications for patient care. The event will provide a platform for discussing the potential impact of Profusa's innovations in the medical field. The presentation of clinical data at a significant conference could lead to increased visibility and interest in Profusa's products, potentially impacting its market position.

Profusa, Inc. will present a late-breaking update on its U.S.-based clinical trial at the Paris Vascular Insights 2025 conference. This presentation is expected to provide insights into the company's ongoing research and development efforts in the vascular health sector. The clinical trial update could significantly influence investor sentiment and the company's strategic direction in the vascular health market.

Profusa, Inc. reported its third quarter business and financial highlights, showcasing advancements in its product pipeline and financial performance. The company emphasized its commitment to innovation in biosensing technology and outlined key milestones achieved during the quarter. Financial results indicated growth in revenue and strategic partnerships aimed at enhancing market presence. Profusa remains focused on expanding its offerings and improving patient outcomes through its proprietary technology. Significant advancements in product development and strategic partnerships are likely to enhance market positioning and investor sentiment.

Profusa, Inc. (PFSA) has outlined a strategic plan to achieve $250 million in revenue by 2030, primarily through the sequential launches of its Lumee™ oxygen and glucose monitoring products. The company aims to leverage these innovative technologies to enhance its market position and drive growth in the health monitoring sector. The planned product launches are expected to significantly impact the company's revenue trajectory and competitive positioning in the health monitoring market.